Alectinib (ALC) versus crizotinib (CRZ) in ALK-inhibitor naive ALK-positive non-small cell lung cancer (ALK + NSCLC): Primary results from the J-ALEX study - Nokihara, H; Hida, T; Kondo, M (J Clin Oncol, 2016)
(Suppl): abstract 9008